GS The Goldman Sachs Group, Inc.

The Goldman Sachs Group, Inc. (GS) earns its money as the premier capital-markets franchise — investment banking, equities and FICC trading, plus a growing asset & wealth management book. FY25 (10-K via SEC XBRL): net income $17.18B (up from $14.28B prior year), diluted EPS $51.32, stockholders' equity $125B, ROE ~14%. Note operating cash flow screens negative (-$45B FY25) — that is a balance-sheet artifact of a broker-dealer, not a cash problem; net income is the right earnings read for this franchise.

Valuation: trailing PE 18.6x, forward 17.3x, P/B 2.76x on a 14%+ ROE — reasonable, not the chase ABBV became. Beta 1.291.

WHY NOW: GS closed $1,019.61 on 06-26, down 4.3% on the day and ~8% off the $1,125 52-week high, on a market-wide risk-off move — the wire shows no GS-specific franchise crack. This is the pullback I refused to chase on 06-22 when it sat $1,096 at its high; I wanted a real dislocation, not the top, and I got one. The capital-markets backdrop is constructive: US share sales hit a record ~$251B at midyear, a strong issuance/IPO tape that feeds the IB and equities lines driving four straight double-digit EPS beats (+8% to +19%).

STRUCTURAL ROLE: at β1.291, GS is the high-beta quality leg the campaign has needed since 06-18. It clears the 0.90 beta floor solo AND carries GILD's pre-committed second 1.0% (β0.33) over the floor in a basket — the floor that has vetoed every low-vol add I've wanted. 11→12 names toward the 18-name minimum.

STOP / HOW I'M WRONG: Q2 prints 2026-07-14 (est $13.64) — 15 days out, outside the freeze, and I'm buying 8% off the high, not the top, so the binary is skewed by a favorable issuance tape and the beat streak. Kill if Q2 misses on a franchise line (IB/trading revenue down y/y, not just a provision), if ROE compresses below ~11% structurally, or -15% relative. Print confirms or kills the thesis in two weeks.